Publications by authors named "Polly De Gorguette D'Argoeuves"
To re-optimize the pneumococcal (Pn) electrochemiluminescence (ECL) assay and to validate and bridge the enhanced assay to the WHO ELISA, to support the Phase III clinical trial program for V114, a 15-valent Pn conjugate vaccine. The Pn ECL assay was re-optimized, validated and formally bridged to the WHO ELISA. The enhanced Pn ECL assay met all prespecified validation acceptance criteria and demonstrated concordance with the WHO ELISA.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to understand pneumococcal colonization and its immune effects in older adults (ages 50-84) since colonization is less common in this group but linked to high disease rates.
- It involved inoculating 64 healthy participants with a specific pneumococcal strain, noting that 39% were successfully colonized, with higher rates in those aged 50-59 compared to those aged 70 and older.
- Results showed that prior vaccination didn’t prevent colonization and that while colonization did increase antiprotein antibodies, it didn’t boost serotype-specific immunity like seen in younger adults, indicating different immune responses in older individuals.
Comparison between a new multiplex electrochemiluminescence assay and the WHO reference enzyme-linked immunosorbent assay to measure serum antibodies against pneumococcal serotype-specific polysaccharides.
Vaccine
April 2019
Background: Two electrochemiluminescence (ECL) assays were developed which, together, can simultaneously measure serum antibodies against pneumococcal capsular polysaccharides (PnPS) for 17 serotypes. The assays were validated for the 13 PnPS included in the 13-valent pneumococcal conjugate vaccine (PCV13). As recommended by the World Health Organization (WHO), we compared the ECL assays with the WHO reference enzyme-linked immunosorbent assay (ELISA) and derived a threshold corresponding to the 0.
View Article and Find Full Text PDFBackground: Pneumococcal vaccines, combining multiple protein antigens, provide an alternative approach to currently marketed vaccines and may provide broader protection against pneumococcal disease. This trial evaluated the safety and immunogenicity of a novel vaccine candidate PnuBioVax in healthy young adults.
Methods: In a Phase 1 double-blind study, 36 subjects (18-40 years) were randomised to receive 3 doses of PnuBioVax, 28 days apart, at one of three dose levels (50, 200, 500 µg) or placebo.